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sOne of the most vexing conundrums in the science and
practice of medicine is the designation of arbitrary “cut-
points” separating what we will consider normal from abnor-
mal. We can pretend that a blood pressure of 121 mm Hg is
different from one of 119 mm Hg, but we should not take that
literally.
In this issue of the Journal, Martin et al. (1) present such
conundrum, in this case, involving the determination of
he “estimated” low-density lipoprotein cholesterol
LDL-C) level in the circulation. This estimated LDL-C is
alculated by the formula: LDL  C  TC  [TG/5 
HDL-C], where TC is total cholesterol in mg/dl, TG is
total triglyceride in mg/dl, and HDL-C is high-density
See page 732
lipoprotein cholesterol in mg/dl. Dividing TG by 5 has been
accepted as an approximation of very low-density lipoprotein
cholesterol (VLDL-C) as long as TG levels are 400 mg/dl.
n a nutshell, Martin et al (1) demonstrate that this assumption
s very weak and, even at TG levels 400 mg/dl, underesti-
ates LDL-C when compared to levels measured directly in
he ultracentrifuge. This is not the first study to question this
ethod of estimating LDL-C, but its gargantuan sample size
akes it by far the largest.
Should we, as a result of this large and well-executed
tudy, abandon estimated LDL-C for a more precise pa-
ameter? There is no shortage of candidates. The simplest
and cheapest) is the non–HDL-C obtained by the formula:
C  HDL-C  non–HDL-C.
This provides an estimate of the cholesterol content of the
po-B–containing, atherogenic lipoproteins in the blood, in-
luding LDL, VLDL, and intermediate-density lipoprotein.
ecause of its inclusiveness, this should be a broader estimate
f circulating atherogenicity than LDL-C alone. It also (by
ubtraction) takes into account the presumed antiatherogenic
roperties of HDL, so that the higher the HDL-C level, the
ower the non–HDL-C. It requires only measurement of TC
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an occasional consultant for Amgen and Pfizer.nd HDL-C, which are widely available and can be measured
ven by fingerstick methods. Conversely, it leaves us dependent
n the cholesterol content of the lipoprotein, which is not a
toichiometric constant.
Direct measurement of apolipoprotein B in the plasma
ight be a better bet because there is 1 molecule of
polipoprotein B in each molecule of LDL. It is a widely
vailable, standardized measurement and does not depend on
he cholesterol content of the particle. It does not, however,
nclude any estimate of HDL, in which it is not present.
Finally, there are ratios of atherogenic to antiathero-
enic particles, including LDL-C/HDL-C and apolipo-
rotein B/apolipoprotein A (the major apolipoprotein of
DL), which, like non-HDL, try to express the net
therogenicity of the blood sample. These have a long
istory of popularity in observational epidemiology but
ave had less acceptance in clinical practice. The reasons
or this are not entirely clear but may be related to the
act that they might encourage clinicians to ignore
reatment of elevated LDL-C levels in patients who also
ave high HDL-C. Unfortunately, our evidence base
oncerning HDL-C is still sufficiently confused to pre-
lude withholding treatment of LDL based solely on a
igh HDL level.
Needless to say, there are many strong and vocal champions
or widespread use of each of these parameters. Unfortunately,
here is not consistent evidence that any of them are reproduc-
bly better than any other, including estimated LDL-C, in
redicting future risk of atherogenic events (2,3).
So what should we do with this carefully executed and
legant report? First, we should not use it to justify the notion
hat we can comfortably abandon following lipid parameters as
e treat patients with lipid-altering drugs. As a result of agents
ow under development, we will soon have the ability to lower
DL-C levels well below 70 mg/dl. As a result, we will have
o contend with the possibility that we can do harm as well as
ood if lipid levels fall too low. At this point, we do not know
here, if at all, such a lower limit might be.
As we examine alternatives to estimated LDL-C, we
hould be mindful that none of the alternatives has been
onvincingly demonstrated to be a better risk predictor
nd that changing recommended parameters in clinical
ettings is a long, slow process, even when the data are
ore solid than they are today. As a start, we might
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non–HDL-C levels. That requires no additional cost.
Non–HDL-C is less cumbersome than estimated
LDL-C and would represent an evolutionary, not revo-
lutionary, step forward.
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